Matches in SemOpenAlex for { <https://semopenalex.org/work/W118624379> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W118624379 endingPage "40" @default.
- W118624379 startingPage "135" @default.
- W118624379 abstract "Increased asthma severity is not only associated with enhanced recurrent hospitalisation and mortality but also with higher social costs. Most cases of asthma are atopic in nature, with the trigger for acute asthma attacks and chronic worsening of inflammation being allergens inducing an immune response through immunoglobulins of IgE class. Currently antiinflammatory treatments are effective for most of asthma patients, but there are subjects whose disease is incompletely controlled by inhaled or systemic corticosteroids and these patients account for about 50% of the healthcare costs of asthma. Omalizumab is a humanized recombinant monoclonal anti-IgE antibody developed for the treatment of allergic diseases and with clear efficacy in adolescent and adult patients with moderate-to-severe allergic asthma.. The anti-IgE antibody inhibits IgE functions blocking free serum IgE and inhibiting their binding to cellular receptors. By reducing serum IgE levels and IgE receptor expression on inflammatory cells in the context of allergic cascade, omalizumab represents a really new approach to the treatment of atopic asthma. Omalizumab improves quality of life of patients with severe persistent allergic asthma that is inadequately controlled by currently available asthma medications. This therapy is well tolerated and significantly improves symptoms, disease control, reducing asthma exacerbations and the need to use high dosage of inhaled corticosteroids. In other words, omalizumab may fulfil an important need in patients with moderate-to-severe asthma." @default.
- W118624379 created "2016-06-24" @default.
- W118624379 creator A5025853697 @default.
- W118624379 creator A5028856583 @default.
- W118624379 creator A5046285091 @default.
- W118624379 creator A5064373109 @default.
- W118624379 creator A5072320542 @default.
- W118624379 creator A5088114568 @default.
- W118624379 date "2010-08-01" @default.
- W118624379 modified "2023-09-26" @default.
- W118624379 title "Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update." @default.
- W118624379 cites W1524017340 @default.
- W118624379 cites W2030556594 @default.
- W118624379 cites W2043990114 @default.
- W118624379 cites W2147173407 @default.
- W118624379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21114196" @default.
- W118624379 hasPublicationYear "2010" @default.
- W118624379 type Work @default.
- W118624379 sameAs 118624379 @default.
- W118624379 citedByCount "3" @default.
- W118624379 countsByYear W1186243792014 @default.
- W118624379 crossrefType "journal-article" @default.
- W118624379 hasAuthorship W118624379A5025853697 @default.
- W118624379 hasAuthorship W118624379A5028856583 @default.
- W118624379 hasAuthorship W118624379A5046285091 @default.
- W118624379 hasAuthorship W118624379A5064373109 @default.
- W118624379 hasAuthorship W118624379A5072320542 @default.
- W118624379 hasAuthorship W118624379A5088114568 @default.
- W118624379 hasConcept C141105273 @default.
- W118624379 hasConcept C151730666 @default.
- W118624379 hasConcept C159654299 @default.
- W118624379 hasConcept C203014093 @default.
- W118624379 hasConcept C207480886 @default.
- W118624379 hasConcept C2776042228 @default.
- W118624379 hasConcept C2778564945 @default.
- W118624379 hasConcept C2779343474 @default.
- W118624379 hasConcept C542903549 @default.
- W118624379 hasConcept C71924100 @default.
- W118624379 hasConcept C86803240 @default.
- W118624379 hasConceptScore W118624379C141105273 @default.
- W118624379 hasConceptScore W118624379C151730666 @default.
- W118624379 hasConceptScore W118624379C159654299 @default.
- W118624379 hasConceptScore W118624379C203014093 @default.
- W118624379 hasConceptScore W118624379C207480886 @default.
- W118624379 hasConceptScore W118624379C2776042228 @default.
- W118624379 hasConceptScore W118624379C2778564945 @default.
- W118624379 hasConceptScore W118624379C2779343474 @default.
- W118624379 hasConceptScore W118624379C542903549 @default.
- W118624379 hasConceptScore W118624379C71924100 @default.
- W118624379 hasConceptScore W118624379C86803240 @default.
- W118624379 hasIssue "4" @default.
- W118624379 hasLocation W1186243791 @default.
- W118624379 hasOpenAccess W118624379 @default.
- W118624379 hasPrimaryLocation W1186243791 @default.
- W118624379 hasRelatedWork W1489784156 @default.
- W118624379 hasRelatedWork W185530636 @default.
- W118624379 hasRelatedWork W1966530570 @default.
- W118624379 hasRelatedWork W1980438888 @default.
- W118624379 hasRelatedWork W1994103789 @default.
- W118624379 hasRelatedWork W2002970486 @default.
- W118624379 hasRelatedWork W2015379751 @default.
- W118624379 hasRelatedWork W2090816535 @default.
- W118624379 hasRelatedWork W2109613137 @default.
- W118624379 hasRelatedWork W2131115843 @default.
- W118624379 hasRelatedWork W2142637315 @default.
- W118624379 hasRelatedWork W2162048015 @default.
- W118624379 hasRelatedWork W2354077771 @default.
- W118624379 hasRelatedWork W2392251565 @default.
- W118624379 hasRelatedWork W2414304138 @default.
- W118624379 hasRelatedWork W2415202961 @default.
- W118624379 hasRelatedWork W2467586878 @default.
- W118624379 hasRelatedWork W2469050955 @default.
- W118624379 hasRelatedWork W2800035713 @default.
- W118624379 hasRelatedWork W3126119907 @default.
- W118624379 hasVolume "42" @default.
- W118624379 isParatext "false" @default.
- W118624379 isRetracted "false" @default.
- W118624379 magId "118624379" @default.
- W118624379 workType "article" @default.